Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Director Kevin Sidow of Carlsmed, Inc. (CARL:CARL) recently purchased 13,333 shares of common stock at a price of $15.00, totaling $199,995. The purchase price sits near the company’s 52-week high of $15.20, with Carlsmed currently maintaining a market capitalization of $384 million. According to InvestingPro analysis, the stock appears to be trading above its Fair Value.
According to a Form 4 filing with the Securities and Exchange Commission, the transaction occurred on July 24, 2025. Sidow also acquired 17,333 shares of Common Stock at $0.00. These shares are related to restricted stock units (RSUs) and will vest in equal annual installments over three years. Additionally, Sidow acquired 28,900 shares of Common Stock upon conversion of Series B Preferred Stock. InvestingPro data shows the company maintains strong liquidity with a current ratio of 6.48, though it remains unprofitable over the last twelve months. Unlock 4 more key insights with InvestingPro.
In other recent news, Carlsmed, Inc. has begun trading on the Nasdaq Global Select Market with its shares priced at $15 each, aligning with its initial public offering (IPO) price. The medical technology company, which focuses on AI-enabled personalized spine surgery solutions, offered 6,700,000 shares of common stock. The IPO is expected to generate gross proceeds of approximately $100.5 million before accounting for underwriting discounts, commissions, and other expenses. The offering is anticipated to close soon, pending customary closing conditions. Additionally, underwriters have a 30-day option to purchase up to an additional 1,005,000 shares at the initial offering price. These developments mark a significant step for Carlsmed as it enters the public market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.